Table. 5—

Microbiological eradication# rates at the post-therapy visit in the microbiologically evaluable population

Uncomplicated groupComplicated group
Levo.Azithro.95% CILevo.Amox./clav.95% CI
Pathogen category
 Gram-positive aerobic pathogens20/22 (90.9)12/15 (80.0)−37.8–16.021/24 (87.5)14/19 (73.7)−40.3–12.6
 Gram-negative aerobic pathogens76/81 (93.8)88/105 (83.8)−19.4–0.675/93 (80.6)88/106 (83.0)−8.9–13.7
Total by pathogen96/103 (93.2)100/120 (83.3)−18.6– −1.196/117 (82.1)102/125 (81.6)−10.6–9.7
Total by patient+75/80 (93.8)72/87 (82.8)−21.2– −0.870/86 (81.4)71/89 (79.8)−13.9–10.7
Pathogen
Enterobacter cloacae1/1 (100.0)3/5 (60.0)0/0 (0.0)0/0 (0.0)
Haemophilus influenzae26/27 (96.3)21/24 (87.5)−25.9–8.325/30§ (83.3)20/20 (100.0)0.8–32.5
Haemophilus parainfluenzae18/20 (90.0)20/23 (87.0)−24.6–18.518/20 (90.0)15/18 (83.3)−31.1–17.8
Klebsiella pneumoniae2/2 (100.0)5/6 (83.3)1/2 (50.0)4/5 (80.0)
Moraxella catarrhalis14/14 (100.0)18/20 (90.0)−26.7–6.710/12 (83.3)16/19 (84.2)−30.0–31.8
Pseudomonas aeruginosa3/3 (100.0)4/6 (66.7)3/5 (60.0)4/5 (80.0)
Staphylococcus aureus7/7 (100.0)0/2 (0.0)4/5 (80.0)3/5 (60.0)
Streptococcus pneumoniae11/12 (91.7)10/11 (90.9)−28.4–26.916/18 (88.9)10/13 (76.9)−42.9–19.0
  • Data are presented as n/N (%), unless otherwise stated. Levo.: levofloxacin; azithro.: azithromycin; CI: confidence interval; amox.: amoxicillin; clav.: clavulanate. #: eradication plus presumed eradication; : two-sided 95% CI around the difference of comparator minus levofloxacin; +: eradication of all pathogens identified at study entry for a patient; §: one patient was inappropriately assessed as a failure by the investigator, even though all of the patient's baseline symptoms were resolved and H. influenzae had been eradicated.